Reportable Segment — Interest Income
Business Segments · Interest IncomeEli Lilly Reportable Segment — Interest Income increased by 62.5% to $65.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 36.0%, from $47.80M to $65.00M. Over 2 years (FY 2022 to FY 2024), Reportable Segment — Interest Income shows an upward trend with a 67.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ3 2025
Rolls up toInterest Income
How to read this metric
An increase suggests higher cash reserves or better yields on invested capital, contributing positively to segment earnings.
Detailed definition
Represents the interest revenue generated by the reportable segment from cash balances, short-term investments, or inter...
Peer comparison
Commonly reported by large-cap pharma companies with significant cash positions.
Metric ID:
lly_segment_reportable_segment_interest_incomeHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.70M | $15.70M | $15.70M | $15.70M | $43.40M | $43.40M | $43.40M | $43.40M | $45.80M | $37.30M | $47.80M | $44.30M | $48.30M | $40.00M | $65.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +176.4% | +0.0% | +0.0% | +0.0% | +5.5% | -18.6% | +28.2% | -7.3% | +9.0% | -17.2% | +62.5% |
| YoY Change | — | — | — | — | +176.4% | +176.4% | +176.4% | +176.4% | +5.5% | -14.1% | +10.1% | +2.1% | +5.5% | +7.2% | +36.0% |
Range$15.70M – $65.00M
CAGR+50.1%
Avg YoY Growth+68.9%
Median YoY Growth+10.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — interest income?
- Eli Lilly (LLY) reported reportable segment — interest income of $65.00M in Q3 2025.
- How has Eli Lilly's reportable segment — interest income changed year-over-year?
- Eli Lilly's reportable segment — interest income increased by 36.0% year-over-year, from $47.80M to $65.00M.
- What is the long-term trend for Eli Lilly's reportable segment — interest income?
- Over 2 years (2022 to 2024), Eli Lilly's reportable segment — interest income has grown at a 67.0% compound annual growth rate (CAGR), from $62.80M to $175.20M.
- What does reportable segment — interest income mean?
- The income earned from interest on cash and investments held by this segment.